Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?

T. M. Aherne, MRCS, MCh¹  M. R. Boland, MRCS, MCh¹  D. Catargiu, MD²  K. Bashar, MRCS, PhD³  T.P. McVeigh, PhD¹  C. Brodie, BSc, MRCPath²  K. J. Sweeney, FRCSI, MD¹,4

¹ Department of Breast Surgery, University Hospital Galway, Galway, Ireland  
² Department of Pathology, University Hospital Galway, Galway, Ireland  
³ Royal College of Surgeons in Ireland, Stephens Green, Dublin, Ireland  
⁴ BreastCheck, Western Unit, Galway, Ireland

Address for correspondence Thomas Aherne, MRCS, MCh, Department of Breast Surgery, University Hospital Galway, Galway, Ireland (e-mail: thomasaherne@rcsi.ie).

Abstract

Introduction  Routine utilization of multigene assays to inform operative decision-making in early breast cancer (EBC) treatment is yet to be established. In this pilot study, we sought to establish the potential benefits of surgical intervention in EBC based on recurrence risk quantification using the Oncotype DX (ODX) assay.

Materials and Methods  Consecutive ODX tests performed over a 9-year period from October 2007 to May 2016 were evaluated. Oncotype scores were classified into high (≥31), medium (18–30), or low-risk (0–17) groups. The primary outcome was breast cancer recurrence. Subgroup analysis offered assessment of the recurrence effect of mode of surgical intervention for patient groups as defined by the oncotype score.

Results  In total 361 patients underwent ODX testing. The mean age and follow-up were 55.25 (± 10.58) years and 38.59 (± 29.1) months, respectively. The majority of patients underwent wide local excision (86.7%) with 8.9 and 4.4% patients having a mastectomy or wide local excision with completion mastectomy, respectively. Fifty-one percent of patients fell into the low risk ODX category with a further 40.2 and 8.5% deemed to be of intermediate and high risk. Five patients (1.38%) had disease recurrence. Comparative analysis of operative groups in each oncotype group revealed no difference in recurrence scores in the low- (<i>p</i> = 0.84) and high-risk groups (<i>p</i> = 0.92) with a statistically significant difference identified in the intermediate risk group (<i>p</i> = 0.002).

Conclusion  To date we have been unable to definitively identify a role for ODX in guiding surgical approach in EBC. There is, however, a need for larger studies to examine this hypothesis.

Keywords
- Oncotype DX
- early breast cancer
- recurrence
- surgery

Multigene tumor assays (MGAs) have offered a greater insight into patient prognosis in early, node negative, hormone receptor positive breast cancers. This further understanding of tumor genetics has allowed oncologists and breast surgeons alike to tailor adjuvant therapy more specifically to individual patients. Despite the proven benefit of adjuvant chemotherapy (AC),¹⁻³ a large proportion of early breast cancer patients is exposed to its negative effects unnecessarily.⁴ In recent years, MGAs have guided the use of AC in this cohort resulting in a significant reduction in the AC-related morbidity.⁵ In addition,
it provides objective, validated data\(^6\) promoting a standardized approach to the management of these cancers across centers globally with its utilization supported by the American Society of Clinical Oncology.\(^7\)

Despite the evolution of systemic directed therapy, locoregional control through surgical intervention and adjuvant radiotherapy remain the mainstay of treatment with proven prognostic benefits.\(^8\)

The specific MGA, Oncotype DX (ODX) 21-gene recurrence score, offers a widely accepted tool to guide prognosis and predict chemotherapy efficacy in this group. Furthermore, the ODX breast cancer assay for ductal carcinoma in situ\(^9\) (DCIS) has emerged as a useful adjunct for predicting patients who stand to benefit from post-breast conservation surgery radiotherapy.\(^10,11\)

However, the routine utilization of MGAs to inform operative decision-making is yet to be established with a paucity of published data. In this pilot study, we sought to identify the relationship of the ODX score and mode of surgical intervention (breast conserving and mastectomy) with a view to establishing the potential benefits of intervention based on recurrence risk quantification. We hypothesize that ODX may predict the prognostic advantages of various surgical interventions and hence inform initial operative decision-making.

**Materials and Methods**

**Study Design and Participants**

In this retrospective cohort study, all patients with stage T1 or T2, node negative, estrogen receptor positive breast cancer undergoing ODX testing were included for analysis. Consecutive ODX tests performed over a 9-year period from October 2007 to May 2016 were evaluated. Study design was guided by the STROBE guidelines for reporting observational trials\(^12\) with full ethical approval granted by the Galway Clinical Research and Ethics Committee.

Pathological assessment of each tumor specimen was performed in the Department of Pathology at University Hospital Galway. All cases were discussed in a multidisciplinary (MDT) setting in the presence of at least one breast surgeon, radiologist, and pathologist. Suitable cases, as described, were referred for ODX scoring with testing performed by Genomic Health Laboratory, Redwood City, California using an established protocol.\(^2\) Oncotype scores were classified as high \((\geq 31)\), medium \((18–30)\), or low risk \((0–17)\) as defined by Paik et al.\(^6\) Adjuvant management was then determined following further MDT and patient consultation.

**Outcomes**

The primary outcome was breast cancer recurrence. Recurrence was confirmed locally or distantly with either historical or radiological confirmation. Further subgroup analysis assessed the recurrence effect of mode of surgical intervention for patient groups as defined by the oncotype score. Secondary end points included tumor characterization, adjuvant therapeutic stratification, and reintervention rates.

**Table 1** Tumor pathological characteristics

| Tumor subtype (n [%]) | Lobular | 57 (16) |
|-----------------------|---------|---------|
|                       | Ductal  | 289 (80) |
|                       | Mixed   | 2 (0.5)  |
|                       | Tubular | 3 (0.8)  |
|                       | Colloid | 6 (1.6)  |
|                       | Other   | 4 (1.1)  |
| Grade (n [%])         | 1       | 40 (11)  |
|                       | 2       | 231 (64) |
|                       | 3       | 90 (25)  |

**Data**

Patient demographic, follow-up, recurrence, and adjuvant therapy data were extracted from the regional Oncology Management System (Citrix Systems Inc. Santa Clara, CA). Tumor detail was obtained from hospital pathology reports. Missing data were identified from review of patient hospital notes. For comparative purposes, patients were cohorted into low-, medium-, and high-risk oncotype score groups. Normally distributed data were reported as mean (standard deviation), while outcome data were reported nominally (percentage) and compared using the chi-squared test. All data were tabulated using Microsoft Excel (Microsoft Corporation, Redmond, WA) and Statistical Package for the Social Sciences (SPSS) software (SPSS Inc., Chicago, IL) was used for data analysis.

**Results**

**Demographic Data**

In total 361 patients underwent oncotype testing over the study period with outcome data available for 353. The mean age was 55.25 years (±10.58). Mean follow-up was 38.59 months (±29.1). All tumors were both hormone receptor positive and HER2, node negative. Mean tumor size was 21.64 mm (±9.05). Further tumor pathological characteristics are summarized in **Table 1**.

**Surgical and Adjuvant Intervention**

The majority of patients underwent a breast conserving wide local excision (WLE) \((n = 313, [86.7\%])\) of the tumor. A further 32 (8.9%) and 16 (4.4%) patients had either a mastectomy or WLE with completion mastectomy, respectively. Of note, 52 (14.4%) patients required reintervention for either a re-excision of margins \((n = 36)\) or completion mastectomy \((n = 16)\).

With regard to overall adjuvant therapy, 148 patients (40.9%) received chemotherapy with 333 (92.2%) undergoing radiotherapy. Three-hundred and fifteen patients (87.2%) undertook regular systemic hormonal therapy. Adjuvant treatment according to oncotype risk group is outlined further in **Table 2**.

**Oncotype Score**

Three-hundred and fifty-three patients had a documented oncotype score over the study period. When stratified

---

The Surgery Journal Vol. 6 No. 2/2020

Aherne et al.
according to recurrence risk, the majority of patients had a “low risk” score (n = 181, [51.3%]). A further 40.2% (n = 142) patients were deemed to be of intermediate risk with a minority [n = 30, (8.5%)] having a high-risk score. Risk groups as defined by oncotype score are further described in Table 2.

Table 2 Patient, tumor, and treatment characteristics as defined by oncotype risk score

| Oncotype risk group | Low | Medium | High |
|---------------------|-----|--------|------|
| Patient number      | 181 | 142    | 30   |
| Age                 | 55.1| 55.3   | 55.9 |
| Tumor size (mm)     | 22.2| 20.6   | 23.25|
| Grade               |     |        |      |
| 1                   | 29  | 10     | 0    |
| 2                   | 122 | 95     | 8    |
| 3                   | 30  | 37     | 22   |
| Follow-up (months)  | 37.1| 41.4   | 37.5 |
| Mode of surgery (n [%]) |    |        |      |
| Wide local excision | 154 (85) | 125 (88) | 28 (93.3) |
| Mastectomy          | 19 (10.5) | 10 (7)  | 1 (3.3)  |
| Wide local excision with completion mastectomy | 8 (4.5) | 7 (5) | 1 (3.3) |
| Surgical reintervention (%) | 15.4 | 12.6 | 16.6 |
| Adjuvant therapy (n [%]) |    |        |      |
| Chemotherapy        | 21 (11.6) | 99 (69.7) | 28 (93.3) |
| Radiotherapy        | 159 (87.8) | 125 (88.65) | 30 (100) |
| Hormonal therapy    | 160 (88.3) | 128 (90.1) | 27 (93.1) |

Note: All figures are means unless otherwise stated. n, number, mm, millimeters.

Disease Recurrence

In total five patients (1.38%) had disease recurrence at a mean of 43.4 months (range: 19–82 months). One patient experienced local recurrence with four further patients developing distant recurrence. Three further patients were diagnosed with DCIS of the contralateral breast during follow-up surveillance.

Subgroup analysis assessing the recurrence effect of mode of surgical intervention for patient groups as defined by the oncotype score is summarized in Table 3. Disease recurrence was 6.66% (2/30) in the high-risk oncotype group with 0.7 (1/142) and 1.1% (2/181) rates of recurrence in the medium- and low-risk oncotype groups, respectively. Two patients undergoing WLE in both the high- and low-risk groups experienced recurrence with one further recurrence identified in the intermediate group following mastectomy. Comparative analysis of operative groups in each oncotype cohort revealed no difference in disease recurrence in the low- (p = 0.84) and high-risk groups (p = 0.92) with a statistically higher rate of recurrence identified in the intermediate-risk mastectomy group (p = 0.002).

Discussion

This study examines the influence of various surgical interventions, based on oncotype risk group, on breast cancer recurrence. Additionally, it further defines the early breast cancer cohort in the genetically diverse West of Ireland. Over the past decade, ODX has emerged as a reliable, externally validated6,13 tool in the management of this patient group allowing effective individualization of therapy. This study aimed to clarify the potential role for ODX in guiding surgical approach.

The majority of early breast cancers consisted of Grade 2 invasive ductal carcinomas with a low overall recurrence rate (1.38%). Adjuvant therapy in the form of radiotherapy and systemic hormone therapy remained consistent across all risk groups. However, the use of AC varied from 11.6% in the low-risk group to 93.3% in the high-risk oncotype group. These figures are in keeping with previous evidence from the region.14 A majority of patients in all groups underwent WLE

Table 3 A comparison of disease recurrence among operative groups as defined by oncotype score

| Oncotype score | Mode of surgery        | Follow-up | Recurrence (n/total) | Subgroup analysis (p-Value) |
|----------------|------------------------|-----------|----------------------|-----------------------------|
| <18            | WLE                    | 37.4      | 2/154                |                             |
|                | Mastectomy             | 35.2      | 0/9                  |                             |
|                | WLE with completion mastectomy | 36.9 | 0/8 | 0.84 |
| 18–31          | WLE                    | 41.5      | 0/125                |                             |
|                | Mastectomy             | 36.7      | 1/10                 |                             |
|                | WLE with completion mastectomy | 47.1 | 0/7 | 0.002 |
| >31            | WLE                    | 37.0      | 2/28                 |                             |
|                | Mastectomy             | 59.0      | 0/1                  |                             |
|                | WLE with completion mastectomy | 30.0 | 0/1 | 0.92 |

Abbreviations: n, number; WLE, wide local excision.
Note: p-Value represents the comparative analysis of the recurrence effect of mode of surgical intervention for patient groups as defined by the oncotype score.
with minorities undergoing mastectomy or WLE with completion. As such, this study remains inadequately powered to definitively identify a role for ODX in determining the surgical approach to these early breast cancers.

The study itself is subject to certain limitations. It is single-centered and retrospective and thus subject to the inherent limitations associated with such studies. While a relatively large sample of 353 patients underwent oncotype testing, recurrence was infrequent and as such standard statistical methods including cox hazard ratios were not incorporated. Furthermore, a majority of recurrences occur after 5 years of endocrine treatment. In keeping with international figures, recurrence rates in the study cohort were less than 3% exposing the study to potentially being underpowered. It is, however, unique in its analysis of ODX testing to evaluate the merits of each surgical mode and the authors would expect larger multicenter studies to add to this knowledge as the role of MGAs develops.

While the management of early breast cancer continues to evolve, local disease control in the form of surgery and radiotherapy remains the cornerstone of therapy. Meta-analysis data has suggested that mode of locoregional control directly influences disease recurrence based on luminal classification. As such tumor subtypes with increased metastatic potential should invariably be approached with more aggressive local intervention. ODX offers an effective tool in further characterizing node negative, hormone receptor positive breast cancers. It has been widely effective in tailoring both chemotherapy and radiotherapy prescription thus limiting disease recurrence in high-risk patients and the debilitating side effects of adjuvant therapy in the lower-risk cohort. The use of MGAs has significant potential to guide mode of surgical intervention; however, to date its merits are yet to be established in the absence of larger multicenter trials.

Conclusion

While MGA, an effective, accessible tool, has offered treating physicians a greater understanding of breast cancer genetics, it may well remain underutilized. In this pilot study, we sought to identify the relationship of the ODX score and mode of surgical intervention with a view to establishing the potential benefits of intervention based on recurrence risk. To date we have been unable to definitively identify a role for ODX in guiding surgical approach. There is, however, a need for larger multicenter studies examining this hypothesis.

Conflicts of Interest

No author reports a conflict of interest.

Acknowledgments

None.

References

1. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320(08):479–484
2. Fisher B, Jeong JH, Bryant J, et al; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364(9437):858–868
3. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997;89(22):1673–1682
4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687–1717
5. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726–3734
6. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;350(27):2817–2826
7. Harris LN, Ismaila N, McShane LM, et al; American Society of Clinical Oncology. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(10):1134–1150
8. Darby S, McGale P, Correa C, et al; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378(9804):1707–1716
9. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013;105(10):701–710
10. Alvarado M, Carter DL, Guenther JM, et al. The impact of genomic testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre. Eur J Cancer 2014;50(16):2763–2770
11. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370(9596):1453–1457
12. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006;8(03):R25
13. McVeigh TP, Hughes LM, Miller N, et al. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre. Eur J Cancer 2014;50(16):2763–2770
14. Regan MM, Neven P, Giobbie-Hurder A, et al; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 2015;152(02):389–398
15. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370(9596):1453–1457
16. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006;8(03):R25
17. McVeigh TP, Hughes LM, Miller N, et al. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre. Eur J Cancer 2014;50(16):2763–2770
18. Regan MM, Neven P, Giobbie-Hurder A, et al; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal breast cancer: the BIG 1-98 randomised clinical trial at 8-1 years median follow-up. Lancet Oncol 2011;12(12):1101–1108
19. Cuzick J, Sestak I, Baum M, et al; ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010;11(12):1135–1141
20. Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 2012;133(03):831–841
21. Wang J, Xie X, Wang X, et al. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: a meta-analysis. Surg Oncol 2013;22(04):247–255